DOCSLIB.ORG

Aldehyde Oxidase Drug Metabolism: Evaluation of Drug Interaction Potential and Allometric Scaling Methods to Predict Human Pharmacokinetics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aldehyde Oxidase Drug Metabolism: Evaluation of Drug Interaction Potential and Allometric Scaling Methods to Predict Human Pharmacokinetics Aldehyde Oxidase Drug Metabolism: Evaluation of Drug Interaction Potential and Allometric Scaling Methods to Predict Human Pharmacokinetics By Rachel Denise Crouch Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmacology December, 2016 Nashville, Tennessee Approved: J. Scott Daniels, Ph.D. Joey V. Barnett, Ph.D. Colleen M. Niswender, Ph.D. C. David Weaver, Ph.D. Neil Osheroff, Ph.D. Wendell S. Akers, Pharm.D., Ph.D. For Mom, Dad, and Robby Colossians 3:17 ii ACKNOWLEDGEMENTS The research described herein was supported by the NIGMS Vanderbilt Training Program in Pharmacological Sciences, the PhRMA Pre-Doctoral Fellowship Program in Pharmacology/Toxicology, and the NIH Division of Loan Repayment Program in Clinical Research. The commitment of these organizations to the development of young scientists in biomedical, pharmaceutical, and translational research is vital to the discovery and advancement of disease diagnosis, treatment, and prevention, and I would like to thank them for the financial provisions they have provided to me throughout my Ph.D. training. In addition, I would like to thank the Lipscomb University College of Pharmacy/Vanderbilt University Department of Pharmacology Pharm.D./Ph.D. Degree Partnership Program for providing me the opportunity to train in an environment of exceptional scientists and a program dedicated to high-quality education. Most notably, I want to express my gratitude toward the individuals who created this program, Drs. Joey Barnett and Scott Akers, for the countless avenues of support they have provided to me. I would not be in the position to present this work today without their support and encouragement—no one, perhaps, is owed more credit for me taking the step toward this achievement than Dr. Akers. Likewise, several prior teachers and mentors at Lipscomb have contributed to my interest in science and my ultimate decision to pursue a career in research. From my undergraduate professors and mentors Drs. Kent Clinger and Ronnie Boone, to my pharmacy school professors and mentors Drs. Michael Fowler and iii Susan Mercer, I am thankful for the instruction, mentoring, and encouragement I received from these individuals. Likewise, I would not have made it through pharmacy school to reach this point without the support and encouragement of my pharmacy classmates Drs. Katie Black and Chris Stokes. In addition to Drs. Barnett and Akers, I am grateful for the others who have graciously served on my dissertation committee. Insightful suggestions from Dr. Colleen Niswender have been an essential contribution to improving the quality and focus of my studies, as have fresh perspectives and ideas from Dr. Neil Osheroff. I am also very appreciative of Dr. Dave Weaver for stepping in to serve as my co-chair alongside Dr. Niswender. Each member of my committee has been tremendously supportive and encouraging, and it has been a pleasure to work with them and gain from their expertise. I would also like to take this time to thank Dr. Matthew Hutzler, who has generously served as an additional mentor to me and a critical contributor to completion of this work. In addition to my committee members, I am especially thankful for the opportunity to work with my mentor, Dr. Scott Daniels, who has been more than just a research advisor, but a life coach, in support of my research, my career aims, as well as my personal well-being. I am appreciative to Dr. Daniels for granting me the freedom to take ownership of my research and for always encouraging me to explore my own ideas. At the same time, I have been fortunate for the opportunity to learn from his expertise and build a foundation for my career. Dr. Daniels has always been my advocate, and I am eternally grateful for his dedicated commitment to my iv success. It has truly been a privilege to train with Dr. Daniels and likewise to have gained a lifelong mentor, colleague, and friend. As for the DMPK lab members, past and present, I am thankful for their friendship and for all that they have graciously taught me. I am especially grateful to Dr. Tom Bridges, who I could always count on to take time to answer a question, Frank Byers for that all he taught and assisted me with and, especially, for making the lab a fun place to be, Jay Foster for always being willing to help and for keeping me entertained in the lab, and Dr. Annie Blobaum and Dr. Chuck Locuson for all their assistance and encouragement. I undoubtedly owe my gratitude to Ryan Morrison for the hours of time he generously dedicated to teaching me everything I know about LC/MS/MS, among countless other concepts and techniques relating to DMPK. His instruction was essential to me reaching this point, as was his friendship. I also thank Sichen Chang, Katrina Brewerer, and several other past labmates for all they have done to aid me. Thanks as well to those in the Lindsely Lab, especially Craig Lindsley, who aided in facilitating the completion of my research. I am also particularly thankful to Matt Mulder for the many ways in which he has assisted me, as well as being a great desk neighbor, and Jeanette Bertron for being a fun, supportive, and encouraging friend. Thanks to everyone else in Cool Springs for all thier help, especially Nathan Kett for keeping the place up and running, as well as many others for creating a fun environment in which to work. There are many others who are owed my gratitude for various means of support in the Department of Pharmacology and VCNDD. I specifically want to thank Karen Gieg, Donna Johnson, and Kristin Riggs for all their v assistance, as well as Dr. Jeffrey Conn and his research group, many members of which have aided me in one way or another. Of course, I must also thank my friends and family, who are too many to name, for all the moral support provided to me over the past several years. I most certainly could not have made it through this challenging time without their support and encouragement. My Mom and Dad have always supported me in whatever I chose to pursue and always believed I could achieve anything I set out to do. I could never repay them for all they have done for me, and I am forever indebted to them for all their love and support. I also want to thank my brother Matt for his love and encouragement, as well as my mother and father-in-law, Bob and Martha, who have treated me like their own daughter. I lastly am infinitely grateful for my husband and best friend, Robby, who has supported me through eight years of pharmacy school and graduate school without complaint. He makes me laugh, makes me think, makes me strong, makes me happy, and I could not make it through life without him. Finally, for all these blessings I have received, I am eternally grateful to God, who already knows the answer before we even conceive the question. vi TABLE OF CONTENTS Page DEDICATION ............................................................................................................................................. ii ACKNOWLEDGEMENTS ...................................................................................................................... iii LIST OF TABLES ...................................................................................................................................xiii LIST OF FIGURES ............................................................................................................................... xvii LIST OF EQUATIONS .......................................................................................................................... xxii LIST OF ABBREVIATIONS .............................................................................................................. xxiii Chapter I. INTODUCTION TO ALDEHYDE OXIDASE ................................................................................. 1 Aldehyde Oxidase Structure .......................................................................................................... 1 Aldehyde Oxidase Substrate Specificity and Reactions ...................................................... 2 Aldehyde Oxidase Catalytic Mechanism ................................................................................... 3 Known Clinical Aldehyde Oxidase Substrates ........................................................................ 4 Known Clinical Aldehyde Oxidase Inhibitors ......................................................................... 7 Aldehyde Oxidase Expression ...................................................................................................... 8 Single human aldehyde oxidase isoform ........................................................................... 8 Species-specific aldehyde oxidase isoforms ..................................................................... 9 Age-dependent aldehyde oxidase expression ...............................................................11 Regulation of aldehyde oxidase expression ...................................................................11 Species-Specific Aldehyde Oxidase Activity ..........................................................................12 Sex Differences in Aldehyde Oxidase Activity ......................................................................13 Endogenous Aldehyde Oxidase Substrates and Physiological Relevance .................15 Human Aldehyde Oxidase Single Nucleotide Polymorphisms ......................................16
Load more

Recommended publications
  • RT² Profiler PCR Array (Rotor-Gene® Format) Human Amino Acid Metabolism I
    RT² Profiler PCR Array (Rotor-Gene® Format) Human Amino Acid Metabolism I Cat. no. 330231 PAHS-129ZR For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Rotor-Gene Q, other Rotor-Gene cyclers Format R Description The Human Amino Acid Metabolism I RT² Profiler PCR Array profiles the expression of 84 key genes important in biosynthesis and degradation of functional amino acids. Of the 20 amino acids required for protein synthesis, six of them (arginine, cysteine, glutamine, leucine, proline, and tryptophan), collectively known as the functional amino acids, regulate key metabolic pathways involved in cellular growth, and development, as well as other important biological processes such as immunity and reproduction. For example, leucine activates mTOR signaling and increases protein synthesis, leading to lymphocyte proliferation. Therefore, a lack of leucine can compromise immune function. Metabolic pathways interrelated with the biosynthesis and degradation of these amino acids include vitamin and cofactor biosynthesis (such as SAM or S-Adenosyl Methionine) as well as neurotransmitter metabolism (such as glutamate). This array includes genes for mammalian functional amino acid metabolism as well as genes involved in methionine metabolism, important also for nutrient sensing and sulfur metabolism. Using realtime PCR, you can easily and reliably analyze the expression of a focused panel of genes involved in functional amino acid metabolism with this array. For further details, consult the RT² Profiler PCR Array Handbook. Shipping and storage RT² Profiler PCR Arrays in the Rotor-Gene format are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products.
    [Show full text]
  • DROSOPHILA INFORMATION SERVICE March 1981
    DROSOPHILA INFORMATION SERVICE 56 March 1981 Material contributed by DROSOPHILA WORKERS and arranged by P. W. HEDRICK with bibliography edited by I. H. HERSKOWITZ Material presented here should not be used in publications without the consent of the author. Prepared at the DIVISION OF BIOLOGICAL SCIENCES UNIVERSITY OF KANSAS Lawrence, Kansas 66045 - USA DROSOPHILA INFORMATION SERVICE Number 56 March 1981 Prepared at the Division of Biological Sciences University of Kansas Lawrence, Kansas - USA For information regarding submission of manuscripts or other contributions to Drosophila Information Service, contact P. W. Hedrick, Editor, Division of Biological Sciences, University of Kansas, Lawrence, Kansas 66045 - USA. March 1981 DROSOPHILA INFORMATION SERVICE 56 DIS 56 - I Table of Contents ON THE ORIGIN OF THE DROSOPHILA CONFERENCES L. Sandier ............... 56: vi 1981 DROSOPHILA RESEARCH CONFERENCE .......................... 56: 1 1980 DROSOPHILA RESEARCH CONFERENCE REPORT ...................... 56: 1 ERRATA ........................................ 56: 3 ANNOUNCEMENTS ..................................... 56: 4 HISTORY OF THE HAWAIIAN DROSOPHILA PROJECT. H.T. Spieth ............... 56: 6 RESEARCH NOTES BAND, H.T. Chyniomyza amoena - not a pest . 56: 15 BAND, H.T. Ability of Chymomyza amoena preadults to survive -2 C with no preconditioning . 56: 15 BAND, H.T. Duplication of the delay in emergence by Chymomyza amoena larvae after subzero treatment . 56: 16 BATTERBAM, P. and G.K. CHAMBERS. The molecular weight of a novel phenol oxidase in D. melanogaster . 56: 18 BECK, A.K., R.R. RACINE and F.E. WURGLER. Primary nondisjunction frequencies in seven chromosome substitution stocks of D. melanogaster . 56: 17 BECKENBACH, A.T. Map position of the esterase-5 locus of D. pseudoobscura: a usable marker for "sex-ratio ..
    [Show full text]
  • Download Thesis
    This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Optimising the use of Azathioprine in the treatment of Inflammatory Bowel Disease Smith, Melissa Ann Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 29. Sep. 2021 Optimising the use of Azathioprine in the treatment of Inflammatory Bowel Disease Dr Melissa Ann Smith MD (Res) 2013 MD thesis Azathioprine in IBD Melissa Ann Smith Table of Contents Table of Contents ...........................................................................................................................
    [Show full text]
  • Metabolic Enzyme Expression Highlights a Key Role for MTHFD2 and the Mitochondrial Folate Pathway in Cancer
    ARTICLE Received 1 Nov 2013 | Accepted 17 Dec 2013 | Published 23 Jan 2014 DOI: 10.1038/ncomms4128 Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer Roland Nilsson1,2,*, Mohit Jain3,4,5,6,*,w, Nikhil Madhusudhan3,4,5, Nina Gustafsson Sheppard1,2, Laura Strittmatter3,4,5, Caroline Kampf7, Jenny Huang8, Anna Asplund7 & Vamsi K. Mootha3,4,5 Metabolic remodeling is now widely regarded as a hallmark of cancer, but it is not clear whether individual metabolic strategies are frequently exploited by many tumours. Here we compare messenger RNA profiles of 1,454 metabolic enzymes across 1,981 tumours spanning 19 cancer types to identify enzymes that are consistently differentially expressed. Our meta- analysis recovers established targets of some of the most widely used chemotherapeutics, including dihydrofolate reductase, thymidylate synthase and ribonucleotide reductase, while also spotlighting new enzymes, such as the mitochondrial proline biosynthetic enzyme PYCR1. The highest scoring pathway is mitochondrial one-carbon metabolism and is centred on MTHFD2. MTHFD2 RNA and protein are markedly elevated in many cancers and correlated with poor survival in breast cancer. MTHFD2 is expressed in the developing embryo, but is absent in most healthy adult tissues, even those that are proliferating. Our study highlights the importance of mitochondrial compartmentalization of one-carbon metabolism in cancer and raises important therapeutic hypotheses. 1 Unit of Computational Medicine, Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 2 Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden. 3 Broad Institute, Cambridge, Massachusetts 02142, USA. 4 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
    [Show full text]
  • Effects of Vitamin B6 Metabolism on Oncogenesis, Tumor Progression and Therapeutic Responses
    Oncogene (2013) 32, 4995–5004 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc REVIEW Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses L Galluzzi1,2,8, E Vacchelli2,3,4, J Michels2,3,4, P Garcia2,3,4, O Kepp2,3,4, L Senovilla2,3,4, I Vitale2,3,4 and G Kroemer1,4,5,6,7,8 Pyridoxal-50-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for 44% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions.
    [Show full text]
  • The Four Aldehyde Oxidases of Drosophila Melanogaster Have
    © 2014. Published by The Company of Biologists Ltd | The Journal of Experimental Biology (2014) 217, 2201-2211 doi:10.1242/jeb.102129 RESEARCH ARTICLE The four aldehyde oxidases of Drosophila melanogaster have different gene expression patterns and enzyme substrate specificities Zvonimir Marelja1, Miriam Dambowsky1, Marco Bolis2, Marina L. Georgiou1, Enrico Garattini2, Fanis Missirlis3,* and Silke Leimkühler1,* ABSTRACT Moco of eukaryotic AOXs contains an equatorial sulfur ligand In the genome of Drosophila melanogaster, four genes coding for required for the catalytic activity of the enzymes (Wahl and aldehyde oxidases (AOX1–4) were identified on chromosome 3. Rajagopalan, 1982; Bray, 1988; Hille, 1996). Phylogenetic analysis showed that the AOX gene cluster evolved via Most animal and plant genomes contain AOX gene clusters that independent duplication events in the vertebrate and invertebrate arose from a series of duplication events from a common XOR lineages. The functional role and the substrate specificity of the ancestor (Forrest et al., 1956; Nash and Henderson, 1982; distinct Drosophila AOX enzymes is unknown. Two loss-of-function Rodríguez-Trelles et al., 2003; Garattini et al., 2008). Rodents and mutant alleles in this gene region, low pyridoxal oxidase (Polpo) and marsupials contain the largest number of AOX functional genes aldehyde oxidase-1 (Aldox-1n1) are associated with a phenotype (AOX1, AOX3, AOX4 and AOX3L1), whereas the human genome characterized by undetectable AOX enzymatic activity. However, the contains one single and functional AOX1 gene (hAOX1) and two genes involved and the corresponding mutations have not yet been non-functional pseudogenes, representing the vestiges of the mouse identified. In this study we characterized the activities, substrate AOX3 and AOX3L1 orthologs (Garattini et al., 2003; Garattini et al., specificities and expression profiles of the four AOX enzymes in D.
    [Show full text]
  • Nimesulide Increases the Aldehyde Oxidase Activity of Humans and Rats
    www.nature.com/aps ARTICLE Nimesulide increases the aldehyde oxidase activity of humans and rats Lei Zhou1, Xiao-yan Pang1, Xiang-yu Hou1, Lu Liu1, Zi-tao Guo1 and Xiao-yan Chen1 An increasing number of drugs are metabolized by aldehyde oxidase (AOX), but AOX-mediated drug interactions are seldom reported due to the lack of appropriate inhibitors and inducers. A recent study reported that nimesulide (NIM) could increase the liver injury risk of methotrexate. The latter was mainly metabolized by AOX to form hepatotoxic 7-hydroxymethotrexate (7-OH MTX). Thus, we speculated that NIM could induce AOX. In this study, we investigated the potential induction of AOX activity by NIM using methotrexate as the probe substrate. Treatment of primary human and rat hepatocytes with NIM (20 μM) for 24 h caused a 2.0- and 3.1-fold, respectively, increase in 7-OH MTX formation. Oral administration of NIM (100 mg·kg−1·d−1, for 5 days) to rats significantly increased the systematic exposure (6.5-fold), liver distribution (2.5-fold), and excretion (5.2-fold for urinary excretion and 2.1-fold for fecal excretion) of 7-OH MTX. The 7-OH MTX formation in liver cytosol from rats pretreated with 20, 50, and 100 mg·kg−1·d−1 NIM for 5 days increased by 1.9-, 3.2-, and 3.7-fold, respectively, compared with that of rats pretreated with the vehicle. We revealed that the elevation of AOX activity was accompanied by an increase in AOX1 protein levels but not the corresponding mRNA levels.
    [Show full text]
  • Characterization of the Human Aldehyde Oxidase: Studies on the FAD Active Site and ROS Generation
    Characterization of the human aldehyde oxidase: studies on the FAD active site and ROS generation Alessandro Foti Dissertation zur Erlangung des akademischen Grades "doctor rerum naturalium" (Dr. rer. nat.) in der Wissenschaftsdisziplin "Biochemie" eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät Institut für Biochemie und Biologie der Universität Potsdam Published online at the Institutional Repository of the University of Potsdam: URN urn:nbn:de:kobv:517-opus4-410107 http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-410107 LIST OF PUBLICATIONS Coelho C, Foti A, Hartmann T, Santos-Silva T, Leimkühler S, Romão MJ. (Achiron et al., 2015) “Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase” Nature Chemical Biolology Oct;11(10):779-83. Foti A, Hartmann T, Coelho C, Santos-Silva T, Romao MJ, Leimkuhler S. (2016) “Optimization of the expression of Human Aldehyde Oxidase for Investigations of Single Nucleotide Polymorphisms.” Drug Metab Dispos. Feb 3. pii: dmd.115.068395. Romão MJ, Coelho C, Santos-Silva T, Foti A, Terao M, Garattini E, Leimkühler S. (2017) “Structural basis for the role of mammalian aldehyde oxidases in the metabolism of drugs and xenobiotics” Current Opinion In Chemical Biology. Jan 23;37:39-47. doi: 10.1016. Foti A, Dorendorf F and Leimkuhler S. (2017) “Single nucleotide polymorphisms cause enhanced radical oxygen species production by human aldehyde oxidase” (manuscript submitted). CONTRIBUTION TO CONFERENCES “Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase” PhD symposium in Luckenwalde, Germany. Nov 2013 oral presentation “Investigation of single nucleotide polymorphisms (SNP) in the active site of human Aldehyde Oxidase”. IX. Molybdenum & Tungsten Enzymes Conference.
    [Show full text]
  • Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer
    International Journal of Molecular Sciences Review Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer Renata Novak Kujundži´c 1,*, Marin Prpi´c 2,3,4, Nikola Ðakovi´c 3,5, Nina Dabeli´c 2, Marko Tomljanovi´c 1, Anamarija Mojzeš 1, Ana Fröbe 2,4 and Koraljka Gall Trošelj 1 1 Laboratory for Epigenomics, Division of Molecular Medicine, Ruder¯ Boškovi´cInstitute, 10000 Zagreb, Croatia; [email protected] (M.T.); [email protected] (A.M.); [email protected] (K.G.T.) 2 Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia; [email protected] (M.P.); [email protected] (N.D.); [email protected] (A.F.) 3 Department of Clinical Oncology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia; [email protected] 4 School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia 5 Institute for Clinical Medical Research and Education, University Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia * Correspondence: [email protected]; Tel.: +385-1-456-0949 Abstract: The activity of nicotinamide N-methyltransferase (NNMT) is tightly linked to the mainte- nance of the nicotinamide adenine dinucleotide (NAD+) level. This enzyme catalyzes methylation of nicotinamide (NAM) into methyl nicotinamide (MNAM), which is either excreted or further me- tabolized to N1-methyl-2-pyridone-5-carboxamide (2-PY) and H2O2. Enzymatic activity of NNMT Citation: Novak Kujundži´c,R.; Prpi´c, is important for the prevention of NAM-mediated inhibition of NAD+-consuming enzymes poly– M.; Ðakovi´c,N.; Dabeli´c,N.; adenosine -diphosphate (ADP), ribose polymerases (PARPs), and sirtuins (SIRTs).
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]
  • RT² Profiler PCR Array (Rotor-Gene® Format) Mouse Amino Acid Metabolism I
    RT² Profiler PCR Array (Rotor-Gene® Format) Mouse Amino Acid Metabolism I Cat. no. 330231 PAMM-129ZR For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Rotor-Gene Q, other Rotor-Gene cyclers Format R Description The Mouse Amino Acid Metabolism I RT² Profiler PCR Array profiles the expression of 84 key genes important in biosynthesis and degradation of functional amino acids. Of the 20 amino acids required for protein synthesis, six of them (arginine, cysteine, glutamine, leucine, proline, and tryptophan), collectively known as the functional amino acids, regulate key metabolic pathways involved in cellular growth, and development, as well as other important biological processes such as immunity and reproduction. For example, leucine activates mTOR signaling and increases protein synthesis, leading to lymphocyte proliferation. Therefore, a lack of leucine can compromise immune function. Metabolic pathways interrelated with the biosynthesis and degradation of these amino acids include vitamin and cofactor biosynthesis (such as SAM or S-Adenosyl Methionine) as well as neurotransmitter metabolism (such as glutamate). This array includes genes for mammalian functional amino acid metabolism as well as genes involved in methionine metabolism, important also for nutrient sensing and sulfur metabolism. Using realtime PCR, you can easily and reliably analyze the expression of a focused panel of genes involved in functional amino acid metabolism with this array. For further details, consult the RT² Profiler PCR Array Handbook. Shipping and storage RT² Profiler PCR Arrays in the Rotor-Gene format are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products.
    [Show full text]
  • Genesymbol Gene Description AASS Aminoadipate-Semialdehyde
    GeneSymbol Gene description AASS aminoadipate-semialdehyde synthase ACVR1 activin A receptor, type I ADAM15 ADAM metallopeptidase domain 15 (metargidin) ADH7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen AGL debranching enzyme, glycogen storage disease type III) AKAP12 A kinase (PRKA) anchor protein (gravin) 12 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid AKR1C3 dehydrogenase, type II) ALDH1A1 aldehyde dehydrogenase 1 family, member A1 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) ALDH3A2 aldehyde dehydrogenase 3 family, member A2 ALS2CL ALS2 C-terminal like ALS2CR3 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 3 AMACR alpha-methylacyl-CoA racemase ANXA1 annexin A1 AOX1 aldehyde oxidase 1 amyloid beta (A4) precursor protein-binding, family B, member 1 APBB1IP interacting protein APOBEC1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 APOE apolipoprotein E APS adaptor protein with pleckstrin homology and src homology 2 domains AQP1 aquaporin 1 (channel-forming integral protein, 28kDa) ARG1 arginase, liver ARHGDIB Rho GDP dissociation inhibitor (GDI) beta ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae) ATF3 activating transcription factor 3 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) Caution, check this probeset carefully. This probeset may detect an unusual splice variant, alternate
    [Show full text]